Krebs Historical Cash Flow
| KREBSBIO | 82.30 0.03 0.04% |
Analysis of Krebs Biochemicals cash flow over time is an excellent tool to project Krebs Biochemicals and future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 815.1 K or Depreciation of 48 M as it is a great indicator of Krebs Biochemicals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Krebs Biochemicals and latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krebs Biochemicals and is a good buy for the upcoming year.
Krebs |
About Krebs Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Krebs balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Krebs's non-liquid assets can be easily converted into cash.
Krebs Biochemicals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Krebs Biochemicals and to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Krebs Biochemicals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Krebs Biochemicals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Krebs Biochemicals and current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. As of now, Krebs Biochemicals' Net Borrowings is increasing as compared to previous years. The Krebs Biochemicals' current Change To Operating Activities is estimated to increase to about 100.3 M, while Change To Inventory is projected to decrease to under 20.4 M.
Krebs Biochemicals cash flow statement Correlations
Click cells to compare fundamentals
Krebs Biochemicals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Krebs Biochemicals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (60.3M) | (16.0M) | (89.6M) | 136.2M | 21.5M | 20.4M | |
| Change In Cash | (171.4M) | 5.4M | (6.1M) | (148K) | 516K | 490.2K | |
| Free Cash Flow | (452.7M) | (400.8M) | (407.4M) | (355.8M) | (50.2M) | (52.7M) | |
| Change In Working Capital | (172.3M) | 21.1M | 159.0M | (98.4M) | 101.5M | 106.6M | |
| Begin Period Cash Flow | 173.2M | 1.7M | 7.1M | 1.0M | 858K | 815.1K | |
| Other Cashflows From Financing Activities | 351.8M | (62.8M) | 71.2M | (29.7M) | (46.9M) | (44.5M) | |
| Depreciation | 46.8M | 51.2M | 63.0M | 65.6M | 67.7M | 48.0M | |
| Other Non Cash Items | 55.6M | 65.5M | 51.2M | 32.6M | 51.2M | 53.7M | |
| Capital Expenditures | 94.1M | 255.1M | 235.2M | 108.7M | 94.2M | 91.7M | |
| Total Cash From Operating Activities | (358.6M) | (145.7M) | (172.2M) | (247.1M) | 23.0M | 24.2M | |
| Net Income | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
| Total Cash From Financing Activities | 277.6M | 376.6M | 395.1M | 373.4M | 55.6M | 52.9M | |
| End Period Cash Flow | 1.7M | 7.1M | 1.0M | 858K | 1.4M | 1.3M | |
| Change To Account Receivables | 27.1M | (977K) | (5.8M) | 3.5M | (13.8M) | (13.1M) | |
| Net Borrowings | (12.6M) | 150.7M | 334.9M | 323.8M | 372.4M | 391.0M | |
| Total Cashflows From Investing Activities | (102.2M) | (225.5M) | (229.0M) | (126.5M) | (113.8M) | (119.5M) | |
| Change To Operating Activities | 97.4M | (135.1M) | 56.8M | 83.1M | 95.6M | 100.3M | |
| Other Cashflows From Investing Activities | (8.1M) | 29.6M | 41.8M | 25.1M | 28.9M | 15.9M | |
| Change To Netincome | 58.0M | 42.7M | 65.5M | 51.1M | 58.8M | 61.8M | |
| Change To Liabilities | 67.7M | 37.9M | 12.6M | (18.7M) | 171.3M | 0.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Krebs Stock
The Cash Flow Statement is a financial statement that shows how changes in Krebs balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Krebs's non-liquid assets can be easily converted into cash.